Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
By Ben Glickman
Shares of Nurix Therapeutics rose Tuesday after the company said it had extended its strategic collaboration with Sanofi.
The stock was up 19% to $16.42 in afternoon trading, reaching its highest intraday level since September 2022. Shares have risen about 55% since the start of the year.
The biopharmaceutical company said that it and Sanofi are looking to nominate a development candidate from the program within the first year of the extended term.
The research program is studying STAT6, a key drug target for certain types of inflammation. The program uses Nurix's platform to identify new compounds that use certain enzymes to affect drug targets.
Under the agreement between the two companies, Sanofi has an option to license drug candidates resulting from the collaboration. Nurix has the option to co-develop and co-promote future products in the U.S. for certain programs.
The deal has been in place since December 2019.
Nurix also on Tuesday said it had presented its findings of clinical responses in the brain for one of its drug candidates, NX-5948, at a conference. Chief Scientific Officer Gwenn Hansen said in a statement that the results suggested a potential role for the compound in the treatment of B-cell lymphomas and some forms of lymphocytic leukemia.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 09, 2024 13:57 ET (17:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software